A Phase II Study of Lapatinib for Brain Metastases in Subjects With ErbB2-Positive Breast Cancer Following Trastuzumab-Based Systemic Therapy and Cranial Radiotherapy.

Trial Profile

A Phase II Study of Lapatinib for Brain Metastases in Subjects With ErbB2-Positive Breast Cancer Following Trastuzumab-Based Systemic Therapy and Cranial Radiotherapy.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Apr 2018

At a glance

  • Drugs Lapatinib (Primary)
  • Indications Advanced breast cancer; Brain metastases
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors GlaxoSmithKline; Novartis
  • Most Recent Events

    • 20 Apr 2018 This trial has been completed in Greece (End date: 2018-03-15), according to European Clinical Trials Database record.
    • 07 Apr 2018 This trial has been completed in Spain (End date: 2018-03-15), according to European Clinical Trials Database record.
    • 04 Apr 2018 This trial has been completed in Austria, according to European Clinical Trials Database
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top